Clinical Trials
4
Active:0
Completed:1
Trial Phases
1 Phases
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (100.0%)Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1
Phase 2
Terminated
- Conditions
- Bladder Cancer
- Interventions
- Drug: Fluorine F 18 Ara-GProcedure: Positron Emission TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2020-01-21
- Lead Sponsor
- Lawrence Fong
- Target Recruit Count
- 4
- Registration Number
- NCT03007719
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Lawrence Fong
- Target Recruit Count
- 15
- Registration Number
- NCT02506114
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Neoadjuvant Atezolizumab in Localized Bladder Cancer
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Lawrence Fong
- Target Recruit Count
- 23
- Registration Number
- NCT02451423
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Ipilimumab and GMCSF Immunotherapy for Prostate Cancer
- First Posted Date
- 2012-02-10
- Last Posted Date
- 2015-10-05
- Lead Sponsor
- Lawrence Fong
- Registration Number
- NCT01530984
- Locations
- 🇺🇸
University of California, San Francisco, California, United States
News
No news found